

## **Apostle Inc Appoints David B. Goldstein, PhD at Columbia University to Scientific Advisory Board**

Press release – Wednesday, January 31, 2018  
For immediate release

**MENLO PARK, CA**, January 31, 2018 – Apostle Inc is pleased to announce the appointment of David B. Goldstein, PhD as a new member to its Scientific Advisory Board. Dr. Goldstein is John E. Borne Professor of Medical and Surgical Research at Columbia University. He is Director of Institute for Genomic Medicine at Columbia University Medical Center. Dr. Goldstein received his PhD degree in Theoretical Population Genetics from Stanford in 1994, and BS in Biology from University of California, Los Angeles.



“I’m pleased to welcome Dr. Goldstein,” said David Ge, CEO and Chairman of Apostle. “David is a renowned leader in genetics and an achieved researcher with a wealth of experience and expertise in human genetic diversity, the genetics of disease, and pharmacogenetics. His advice will add tremendous value to our company as we further our mission of bringing innovative technologies to help our community with the early detection of cancer and other potential clinical applications.”

Dr. Goldstein is Elected Member of AAAS. He was the recipient of Royal Society Wolfson Research Merit Award. His research at Columbia focuses on many aspects of human genetic variation including human genetic diversity, the genetics of disease, and pharmacogenetics.

### **About Apostle Inc**

Apostle Inc is a biotechnology company in Menlo Park, CA, aiming to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle’s innovations include Apostle MiniMax™, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw.

More information can be found at [www.apostlebio.com](http://www.apostlebio.com).  
Contact: [info@apostlebio.com](mailto:info@apostlebio.com)